ECSP11011468A - Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6 - Google Patents
Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6Info
- Publication number
- ECSP11011468A ECSP11011468A EC2011011468A ECSP11011468A ECSP11011468A EC SP11011468 A ECSP11011468 A EC SP11011468A EC 2011011468 A EC2011011468 A EC 2011011468A EC SP11011468 A ECSP11011468 A EC SP11011468A EC SP11011468 A ECSP11011468 A EC SP11011468A
- Authority
- EC
- Ecuador
- Prior art keywords
- phenyl
- hydrogen
- homopiperazine
- homopiperazinyl
- piperazine
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 4
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 title abstract 2
- -1 HOMOPIPERAZINYL Chemical class 0.000 title abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Chemical group 0.000 abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos de N-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina), con composiciones farmacéuticas que contienen a los mismos y su uso en terapias. Los compuestos tienen propiedades terapéuticas valiosas y son apropiados, en particular, para tratar enfermedades que responden a la modulación del receptor de serotonina 5-HT6. Consta gráfico en dondeX es un enlace o un grupo N-R4;R1 es hidrógeno o metilo;R2 es hidrógeno o metilo;R3 es hidrógeno, C1-C3 alquilo, flúor, C1-C2 alcoxi o C1-C2 alcoxi fluorado;R4 es hidrógeno, C1-C4 alquilo, C3-C4 cicloalquilo o C3-C4 cicloalquil-CH2-;R5 es hidrógeno, flúor, cloro, C1-C2 alquilo, C1-C2 alquilo fluorado, C1-C2 alcoxi o C1-C2 alcoxi fluorado;R6 es hidrógeno, flúor o cloro; yn es 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17405409P | 2009-04-30 | 2009-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011468A true ECSP11011468A (es) | 2011-12-30 |
Family
ID=42236832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011468A ECSP11011468A (es) | 2009-04-30 | 2011-11-21 | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8076326B2 (es) |
| EP (1) | EP2432769B1 (es) |
| JP (1) | JP5718898B2 (es) |
| KR (1) | KR20120016639A (es) |
| CN (1) | CN102459197B (es) |
| AR (1) | AR076507A1 (es) |
| AU (1) | AU2010243585B2 (es) |
| BR (1) | BRPI1011875A2 (es) |
| CA (1) | CA2759482A1 (es) |
| CL (1) | CL2011002653A1 (es) |
| CO (1) | CO6450637A2 (es) |
| CR (1) | CR20110604A (es) |
| DO (1) | DOP2011000326A (es) |
| EC (1) | ECSP11011468A (es) |
| ES (1) | ES2536779T3 (es) |
| IL (1) | IL215642A (es) |
| MX (1) | MX2011011520A (es) |
| NZ (1) | NZ595698A (es) |
| PE (1) | PE20120881A1 (es) |
| RU (1) | RU2535200C2 (es) |
| SG (1) | SG175187A1 (es) |
| TW (1) | TWI465438B (es) |
| UA (1) | UA107080C2 (es) |
| UY (1) | UY32604A (es) |
| WO (1) | WO2010125134A1 (es) |
| ZA (1) | ZA201107569B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| WO2009147188A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| ES2383246T3 (es) | 2008-06-05 | 2012-06-19 | Glaxo Group Limited | 4-amino-indazoles |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
| US8343959B2 (en) * | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| WO2012059432A1 (en) * | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
| US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| KR20150092764A (ko) * | 2012-12-10 | 2015-08-13 | 에프. 호프만-라 로슈 아게 | RORc 조절인자로서의 벤질 설폰아마이드 유도체 |
| CN105121404A (zh) * | 2013-03-15 | 2015-12-02 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的芳基磺酰胺和氨基磺酸衍生物 |
| EP3083588B1 (en) | 2013-12-20 | 2020-12-09 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| US9840482B2 (en) | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
| US20250228851A1 (en) * | 2021-10-20 | 2025-07-17 | Yousef Najajreh | Allosteric inhibitor compounds for overcoming cancer resistance |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| EP0994862B1 (en) * | 1997-07-11 | 2005-06-01 | SmithKline Beecham plc | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
| GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9818914D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| SE0002739D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
| EP1406884A1 (en) | 2001-05-11 | 2004-04-14 | Biovitrum Ab | Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
| CN1800185A (zh) * | 2001-06-11 | 2006-07-12 | 比奥维特罗姆股份公司 | 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ii型糖尿病的药物的应用 |
| MXPA04001250A (es) * | 2001-08-10 | 2004-05-27 | Hoffmann La Roche | Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6). |
| JP4467307B2 (ja) * | 2002-02-22 | 2010-05-26 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体 |
| GB0305575D0 (en) | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| PE20060574A1 (es) | 2004-07-28 | 2006-06-24 | Glaxo Group Ltd | Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs) |
| GB0419192D0 (en) * | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
| JP2009533325A (ja) * | 2006-03-17 | 2009-09-17 | アストラゼネカ・アクチエボラーグ | ５−ｈｔ６調節剤としての新規なテトラリン |
| BRPI0710177A2 (pt) * | 2006-04-19 | 2012-05-29 | Abbott Gmbh & Co Kg | arilsulfonas heterocìclicas adequadas para tratar distúrbios que respondem à modulação do receptor 5ht6 de serotonina |
| WO2008087123A2 (en) | 2007-01-16 | 2008-07-24 | Solvay Pharmaceuticals B.V. | Use of 5-ht6 antagonists to prevent relapse into addiction |
-
2010
- 2010-04-29 AU AU2010243585A patent/AU2010243585B2/en not_active Ceased
- 2010-04-29 SG SG2011074325A patent/SG175187A1/en unknown
- 2010-04-29 MX MX2011011520A patent/MX2011011520A/es active IP Right Grant
- 2010-04-29 PE PE2011001879A patent/PE20120881A1/es not_active Application Discontinuation
- 2010-04-29 NZ NZ595698A patent/NZ595698A/en not_active IP Right Cessation
- 2010-04-29 CA CA2759482A patent/CA2759482A1/en not_active Abandoned
- 2010-04-29 CN CN201080030335.8A patent/CN102459197B/zh not_active Expired - Fee Related
- 2010-04-29 WO PCT/EP2010/055789 patent/WO2010125134A1/en not_active Ceased
- 2010-04-29 KR KR1020117028393A patent/KR20120016639A/ko not_active Ceased
- 2010-04-29 UA UAA201114123A patent/UA107080C2/ru unknown
- 2010-04-29 EP EP10719748.5A patent/EP2432769B1/en active Active
- 2010-04-29 JP JP2012507761A patent/JP5718898B2/ja not_active Expired - Fee Related
- 2010-04-29 ES ES10719748.5T patent/ES2536779T3/es active Active
- 2010-04-29 BR BRPI1011875A patent/BRPI1011875A2/pt not_active IP Right Cessation
- 2010-04-29 RU RU2011148583/04A patent/RU2535200C2/ru not_active IP Right Cessation
- 2010-04-30 AR ARP100101465A patent/AR076507A1/es not_active Application Discontinuation
- 2010-04-30 US US12/770,837 patent/US8076326B2/en not_active Expired - Fee Related
- 2010-04-30 UY UY0001032604A patent/UY32604A/es not_active Application Discontinuation
- 2010-04-30 TW TW099113996A patent/TWI465438B/zh not_active IP Right Cessation
-
2011
- 2011-10-09 IL IL215642A patent/IL215642A/en not_active IP Right Cessation
- 2011-10-14 ZA ZA2011/07569A patent/ZA201107569B/en unknown
- 2011-10-25 CL CL2011002653A patent/CL2011002653A1/es unknown
- 2011-10-25 DO DO2011000326A patent/DOP2011000326A/es unknown
- 2011-11-03 CO CO11149288A patent/CO6450637A2/es active IP Right Grant
- 2011-11-15 CR CR20110604A patent/CR20110604A/es unknown
- 2011-11-21 EC EC2011011468A patent/ECSP11011468A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011468A (es) | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6 | |
| UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
| PE20190913A1 (es) | Derivados aromaticos de sulfonamida | |
| PA8845601A1 (es) | Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) | |
| DOP2013000315A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| CR20140107A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| DOP2011000217A (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| CO2019012473A2 (es) | Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos | |
| EA201691447A1 (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| MX2020010879A (es) | Carboxamidas biciclicas y metodos de uso de las mismas. | |
| UY30032A1 (es) | Compuestos de cinolina, composiciones farmacéuticas que los contienen y procesos para la preparación y uso de los mismos | |
| UY31159A1 (es) | Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| UY36263A (es) | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso | |
| UY35090A (es) | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 | |
| PE20170083A1 (es) | Nuevos compuestos | |
| ECSP13012453A (es) | 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3 | |
| EA202190966A1 (ru) | Пролекарства антагонистов cgrp | |
| DK2201002T3 (da) | 5-HT7-receptorantagonister | |
| UY34408A (es) | Nuevos moduladores de trpv3 | |
| MX2017007114A (es) | Una triazolopiridazina como un modulador de cinasa. | |
| UY35685A (es) | Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso |